Participants 56 93 7
postmenopausal breast cancer patients
Participants 432 509 5
metastatic breast cancer patients with previous exposure to endocrine therapy
Participants 1056 1183 4
primary tumor tissue from patients who participated in a randomized trial of adjuvant tamoxifen (1-3 years) versus observation.
